Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Apogee Therapeutics Inc APGE

Healthcare Biotechnology
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the... see more

Recent & Breaking News (NDAQ:APGE)

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2025

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

GlobeNewswire May 12, 2025

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

GlobeNewswire May 12, 2025

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

GlobeNewswire May 1, 2025

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

GlobeNewswire March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

GlobeNewswire March 3, 2025

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

GlobeNewswire February 28, 2025

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire February 25, 2025

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

GlobeNewswire February 3, 2025

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire January 29, 2025

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

GlobeNewswire December 10, 2024

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

GlobeNewswire December 2, 2024

Apogee Therapeutics Announces Agenda for Virtual R&D Day

GlobeNewswire November 29, 2024

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

GlobeNewswire November 18, 2024

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

GlobeNewswire November 12, 2024

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire November 4, 2024

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

GlobeNewswire October 24, 2024

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

GlobeNewswire October 16, 2024

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

GlobeNewswire September 12, 2024

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

GlobeNewswire September 9, 2024